Cure8 research brief
The study links a polyphenol-rich diet to a specific microbiome change and a microbial metabolite (4-HPAA) that reduced inflammation in mouse models — offering a possible mechanism by which diet could influence Crohn's disease-related intestinal inflammation.
If validated in humans, this pathway could point to new nutrition-based or metabolite-targeted strategies to modulate immune cells and protect the intestinal barrier.
Researchers, clinicians, and informed patients interested in IBD, microbiome–metabolite mechanisms, and diet-based interventions.
This research article reports that a polyphenol-rich (Aronia berry) diet reduced intestinal inflammation in mouse models of colitis and that changes in the gut microbiome—especially enrichment of Flavonifractor plautii—were linked to higher levels of the microbial metabolite 4-hydroxyphenylacetic acid (4-HPAA). Supplementing mice with F.
plautii or administering 4-HPAA partly reproduced the protective intestinal effects. In macrophage experiments, 4-HPAA shifted cells away from a pro-inflammatory state and promoted oxidative metabolism; mechanistic work indicated 4-HPAA stabilizes SIRT1 by reducing its ubiquitination and proteasomal degradation, activating SIRT1–PGC-1α signaling.
The authors propose a diet→microbe→metabolite→host signaling pathway (Aronia polyphenols → F. plautii → 4-HPAA → SIRT1) that links nutritional intervention to macrophage immunometabolism and epithelial barrier protection in mouse models.
Preclinical study in mouse colitis models and in vitro macrophage experiments; does not demonstrate efficacy or safety in humans. The article is an abstract/full-text report in a peer-reviewed journal but remains translational research.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Jiangsu Provincial Commission of Health and Family Planning - No.M2025006
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Colon-targeted delivery systems aim to concentrate drugs in the colon, which could improve effectiveness and reduce systemic side effects for IBD and colorectal cancer treatments. Understanding these approaches helps...
The review explains why many patients still fail current therapies and summarizes promising new research directions (microRNA, microbiome therapies, stromal cell approaches) that could change treatment strategies.
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
